证券日报网讯12月25日，皓元医药在互动平台回答投资者提问时表示，公司《2025年度"提质增效重回 报"专项行动方案半年度评估报告》第4页披露，公司设有8个商务中心、6个研发中心及4个生产基地。 其中，商务中心广泛布局于中国、美国、欧洲、印度、中国香港、日本、韩国及东南亚地区，依托国内 外商务人员与国内专业技术团队的跨区域协同机制，可快速响应全球超万家客户的需求。经过持续拓 展，公司已与多家跨国医药巨头、全球知名高校、科研院所及CRO公司建立合作，并与众多海外知名 药物研发试剂专业经销商形成稳定合作关系。目前，在美国及中国大部分区域，公司已实现当天下单、 次日送达，为客户提供了便捷的采购体验，时效性优于进口品牌，在行业内处于领先水平。2025年上半 年，公司境外收入达5.6亿元，同比增长39.8%；境外收入占主营业务收入的比重为43.0%，同比提升近5 个百分点。 ...

（文章来源：证券日报） 证券日报网讯 12月21日晚间，皓元医药发布公告称，股东苏信基金拟于2025年12月26日至2026年3月25 日通过集中竞价减持不超过546，405股，占公司总股本0.26%，减持原因为基金到期、股东自身财务需 求等安排。 ...

公告显示，苏信基金持有公司54.64万股股份，占减持计划实施前公司总股本的0.26%。这也意味着，此 次减持系清仓式减持。 北京商报讯（记者 丁宁）12月21日晚间，皓元医药（688131）发布公告称，因基金到期、股东自身财 务需求等安排，公司股东苏民投君信（上海）产业升级与科技创新股权投资合伙企业（有限合伙）（以 下简称"苏信基金"）拟通过集中竞价的方式减持不超过54.64万股公司股份，拟减持比例不超过公司当 前总股本的0.26%。 ...

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The biopharmaceutical investment and financing environment has shown significant recovery since the second half of 2025, with a total financing amount of USD 30.32 billion from July to November 2025, representing a year-on-year increase of 30.90% [4] - The number of new drug IND applications stabilized in 2025, with approximately 1,897 applications from January to November, reflecting a year-on-year growth of about 7.91% [4] - The demand for CRO services has shown a clear turning point, and the report continues to recommend opportunities in the innovative drug industry chain (CXO + research services) for 2026 [4] Summary by Sections Industry Performance - The biopharmaceutical sector experienced a decline of 0.14% in the third week of December 2025, outperforming the CSI 300 index by 0.14 percentage points, ranking 22nd among 31 sub-industries [7][14] - The offline pharmacy sector saw the highest increase, rising by 5.59%, while the chemical preparation sector had the largest decline at 2.1% [18][22] Investment Opportunities - The report highlights the strong performance of leading CXO and research service companies, with many exceeding earnings expectations. Companies like WuXi AppTec and Tigermed have raised their earnings guidance for 2025 [5] - The report recommends a valuation switch opportunity for leading CXO and research service companies, given the continuous improvement in demand [5] Clinical Research Organizations (CRO) - There has been a notable improvement in orders for preclinical and clinical CROs, with expectations for significant improvements in financial statements for 2026 [6] - The report anticipates that the market demand will continue to focus on leading companies as the capacity of clinical CROs is expected to be streamlined [6] Monthly and Weekly Recommendations - The report recommends a monthly investment portfolio including companies such as Sanofi, Innovent Biologics, and others, focusing on innovative drug opportunities and valuation switch [8]

每经AI快讯，12月21日，皓元医药(688131.SH)公告称，股东苏信基金因基金到期、股东自身财务需求 等安排，拟通过集中竞价方式减持不超过54.64万股公司股份，占公司当前总股本的0.26%。减持期间为 2025年12月26日至2026年3月25日。拟减持股份来源为公司首次公开发行前及上市后权益分派资本公积 转增股本取得的股份。 ...

人民财讯12月21日电，皓元医药(688131)12月21日公告，持股0.26%的股东苏民投君信(上海)产业升级与 科技创新股权投资合伙企业(有限合伙)(简称"苏信基金")拟通过集中竞价方式，减持公司股份不超过 54.64万股，拟减持比例不超过公司当前总股本的0.26%。 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-130 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 因基金到期、股东自身财务需求等安排，苏信基金拟通过集中竞价的方式减 持不超过 546,405 股公司股份，拟减持比例不超过公司当前总股本的 0.26%。本 次减持计划自本公告披露之日起 3 个交易日后的 3 个月内进行。 近日，公司收到股东苏信基金出具的《关于股份减持计划的告知函》，现将 具体情况公告如下： | 股东名称 | 苏民投君信（上海）产业升级与科技创新股权投资合伙 | | | --- | --- | --- | | | 企业（有限合伙） | | | 股东身份 | 控股股东、实控人及一致行动人 √否 | □是 | | | 直接持股 √否 5%以上股东 | □是 | 一、减持主体的基本情况 1 | | 董事、监 ...

智通财经APP讯，皓元医药(688131.SH)发布公告，因基金到期、股东自身财务需求等安排，苏信基金 拟通过集中竞价的方式减持不超过54.64万股公司股份，拟减持比例不超过公司当前总股本的0.26%。本 次减持计划自公告披露之日起3个交易日后的3个月内进行。 ...

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the promising data from CTLA-4 drugs, suggesting potential investment opportunities in related areas [3][5] - The pharmaceutical index experienced a slight decline of 0.14% from December 15 to December 19, 2025, but showed a relative outperformance of 0.14% against the CSI 300 index [5] - The report emphasizes the importance of innovative drugs as a key investment theme for 2026, with a focus on companies that are expected to show clear performance trends and potential reversals in operations [5][41] Summary by Sections 1. CTLA-4 Target - CTLA-4 is identified as a significant immune checkpoint that can inhibit T cell activation, presenting potential value in cancer immunotherapy [8][9] - The CTLA-4 monoclonal antibody Gotistobart shows promising clinical trial results for squamous non-small cell lung cancer (sqNSCLC) patients who are resistant to immunotherapy [14][15] - Gotistobart's innovative mechanism targets Treg cells in the tumor microenvironment, potentially leading to a new paradigm in tumor immunotherapy [20][24] 2. Industry Perspective - The report maintains that innovative drugs should be the main focus for the year, while also considering manufacturing exports and aging-related consumption as relatively undervalued assets [25][41] - The pharmaceutical index has shown a year-to-date increase of 14.49%, with a notable number of stocks experiencing significant gains [25][26] - The report suggests that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs opening new growth avenues for companies [41][42] 3. Investment Recommendations - Recommended stocks include innovative drug companies such as Xinyi Tai, Zai Jian Pharmaceutical, and others, as well as companies in the medical device sector [5][45] - The report advises focusing on companies with strong performance trends and those expected to benefit from the aging population and outpatient consumption [42][44] - The report also highlights the potential of AI in the pharmaceutical sector, suggesting that related stocks may perform well in the coming years [42][44]

格隆汇12月21日丨皓元医药(688131.SH)公布，因基金到期、股东自身财务需求等安排，苏信基金拟通 过集中竞价的方式减持不超过546,405股公司股份，拟减持比例不超过公司当前总股本的0.26%。本次减 持计划自本公告披露之日起3个交易日后的3个月内进行。 ...